Animal Model Market Expansion Driven by Rising Demand for Advanced Preclinical Research 2026–2034
- 5 days ago
- 10 min read
The global Animal Model Market is expanding as pharmaceutical and biotechnology companies increase investments in preclinical drug discovery, biomedical research, disease modeling, toxicology testing, vaccine development, and precision medicine. Animal models play an important role in evaluating therapeutic efficacy and safety before clinical studies. Increasing adoption of genetically engineered models, humanized mice, patient-derived xenografts, and disease-specific models is improving the ability of researchers to investigate complex diseases and develop targeted therapies.
According to Fortune Business Insights, the global animal model market was valued at USD 2.69 billion in 2025 and is projected to grow from USD 2.93 billion in 2026 to USD 5.87 billion by 2034, exhibiting a CAGR of 9.07% during the forecast period.
Why is the Animal Model Market Growing?
The increasing demand for preclinical testing and biomedical research is one of the major factors supporting market growth. Pharmaceutical and biotechnology companies use animal models to evaluate drug candidates, investigate disease mechanisms, assess toxicity, and study therapeutic responses before progressing to human trials.
Animal models are increasingly used for:
Cancer research
Infectious disease research
Immunology
Neurological disorders
Metabolic diseases
Toxicology studies
Vaccine development
Gene-editing research
Drug discovery
Precision medicine
Antibody development
Regenerative medicine
Fortune Business Insights reports that more than 62% of global drug-discovery studies involve animal testing during early-stage therapeutic evaluation, while the U.S. market benefits from extensive pharmaceutical R&D infrastructure and government-backed biomedical research programs.
Key Market Trends Shaping Industry Growth
Increasing Adoption of Genetically Engineered Models
Genetically engineered mice are increasingly used to reproduce specific human disease characteristics. These models support research into oncology, neurological diseases, metabolic disorders, autoimmune conditions, and immunotherapy.
Growing Use of Humanized Animal Models
Humanized animal models are gaining importance in advanced immunology and oncology research. These models can help researchers study human-specific biological responses and evaluate new therapeutic candidates.
Increasing Use of CRISPR Gene-Editing Technology
CRISPR technology has significantly improved the development of customized animal models. Researchers can create targeted genetic modifications more efficiently, accelerating the development of disease-specific models.
Expansion of Patient-Derived Xenograft Models
Patient-derived xenograft models are increasingly being used in cancer research and personalized medicine. These models can help researchers evaluate treatment responses using tumor samples derived from individual patients.
Growing Demand for Precision Medicine
The expansion of precision medicine is increasing demand for customized animal models that can mimic specific genetic and molecular characteristics of human diseases.
Increasing Adoption of Digital Phenotyping
Research laboratories are integrating digital phenotyping systems, automated monitoring, imaging, and data-analysis technologies to improve experimental consistency and collect more detailed behavioral and physiological information.
Expansion of Contract Research Organizations
Pharmaceutical companies are increasingly outsourcing preclinical research to contract research organizations (CROs). CROs are expanding breeding facilities, pathogen-free environments, and specialized disease-model capabilities to meet outsourcing demand.
Growing Partnerships Between Genomics and Animal-Model Providers
Genomic research companies and animal-model suppliers are increasingly collaborating to accelerate precision disease modeling and customized model development.
Increasing Focus on Standardized Preclinical Research
Regulatory agencies are emphasizing standardized preclinical testing procedures, which is increasing demand for validated animal models, controlled laboratory environments, and consistent research protocols.
Market Dynamics
Driver: Rising Demand for Preclinical Drug Discovery and Biomedical Research
Increasing pharmaceutical R&D is a primary driver of the Animal Model Market. Biopharmaceutical companies are expanding research programs in oncology, immunotherapy, neurological disorders, metabolic diseases, and rare diseases, creating greater demand for specialized models.
Academic institutions and government-funded research programs are also increasing procurement of laboratory animals for genetic studies, vaccine development, toxicology, and translational research.
Restraint: Ethical Concerns and Regulatory Compliance
Animal welfare concerns remain an important market restraint. North America and Europe are implementing increasingly stringent regulations covering laboratory-animal housing, monitoring, veterinary oversight, and humane treatment.
These requirements can increase research costs and extend project timelines. Public opposition to animal experimentation is also encouraging the development of in vitro assays, organ-on-chip systems, and other alternative research models.
Opportunity: Expansion of Personalized Medicine and Gene Editing
Personalized medicine provides a major growth opportunity because pharmaceutical companies require models that more closely reproduce human genetic and molecular conditions. CRISPR and related gene-editing technologies are making customized disease-model development more efficient.
Patient-derived xenograft models and customized immunodeficient mice are also creating opportunities in oncology and immunotherapy research.
Challenge: High Maintenance Costs and Complex Breeding
Maintaining laboratory animals requires specialized facilities, controlled environmental conditions, biosecurity systems, veterinary oversight, and trained personnel. Genetically modified colonies can require complex breeding programs and longer development timelines.
Shortages of skilled laboratory-animal professionals, supply-chain disruptions, and the increasing complexity of multi-gene disease models can further increase costs.
For detailed market insights: https://www.fortunebusinessinsights.com/animal-model-market-116750
Market Segmentation Analysis
By Animal Type
Mice Segment Dominates
Mice account for nearly 71% of the global Animal Model Market, making them the dominant animal type. Their high genetic similarity to humans, relatively rapid breeding cycles, availability of established strains, and compatibility with genetic modification make mice particularly valuable for pharmaceutical and biomedical research.
Mice are widely used in:
Oncology
Immunology
Neurology
Metabolic disease research
Toxicology
Gene-editing research
Drug discovery
Antibody development
Fortune Business Insights reports that more than 58% of oncology preclinical studies globally involve genetically engineered mouse models for therapeutic evaluation.
Humanized mice are also gaining use in personalized medicine, antibody development, and cancer immunotherapy.
Guinea Pig Segment
Guinea pigs contribute approximately 18% of the market. They are particularly valuable for infectious disease, respiratory disease, immunology, vaccine, dermatology, allergy, and auditory-system research.
Guinea pigs continue to be used in tuberculosis and influenza research because of physiological and immune characteristics relevant to specific research applications.
Their use is also increasing in hypersensitivity testing, antimicrobial-resistance studies, and vaccine safety research.
By Application
Cancer Research Segment Dominates
Cancer research accounts for approximately 46% of the global Animal Model Market, making it the leading application. The expansion of oncology drug development, cancer immunotherapy, targeted treatments, and personalized medicine is increasing demand for genetically engineered mice, humanized models, and patient-derived xenografts.
CROs are also expanding pathogen-free and specialized breeding facilities to support increasing oncology-research outsourcing.
Infectious Disease Research
Infectious disease research remains an important application. Animal models are used for studying pathogens, evaluating vaccines, testing antiviral and antimicrobial treatments, and understanding host immune responses. Demand increased following intensified research into viral outbreaks and vaccine development.
Immunology
Animal models are increasingly used for immunology and immunotherapy research, particularly humanized mouse models capable of supporting more sophisticated studies of immune responses.
Neurological Disorders
Customized models for neurological and neurodegenerative diseases are gaining adoption as pharmaceutical companies increase investment in neuroscience research.
Regional Insights
North America Leads the Global Market
North America accounted for 41% of the global Animal Model Market in 2025. The region benefits from extensive pharmaceutical R&D infrastructure, advanced laboratory-animal facilities, strong biotechnology clusters, and government-backed biomedical research programs.
The United States is the dominant regional contributor. More than 48% of U.S. preclinical research projects rely on specialized rodent models for therapeutic validation and toxicity assessment, according to Fortune Business Insights.
Investment in cancer immunotherapy, rare-disease research, transgenic mice, customized models, and CRO services is supporting regional growth.
Europe
Europe accounts for approximately 28% of the global market. Strong pharmaceutical manufacturing, biotechnology innovation, academic research networks, and translational medicine programs are supporting demand.
Germany represents approximately 31% of Europe's market, while the U.K. accounts for approximately 24%.
Asia Pacific
Asia Pacific represents approximately 23% of the global market. Rapid pharmaceutical expansion, increasing biotechnology investment, healthcare modernization, and growth in preclinical research are supporting regional adoption.
Competitive Landscape
The global Animal Model Market is competitive, with pharmaceutical companies, biotechnology firms, research organizations, and specialized animal-model providers focusing on genetically engineered models, humanized mice, disease-specific models, customized breeding, and preclinical research services. Companies are increasingly investing in precision disease modeling, gene editing, and specialized animal colonies to support drug discovery and translational research.
Major Companies Operating in the Market
Charles River Laboratories
The Jackson Laboratory
Taconic Biosciences, Inc.
Envigo
Crown Bioscience
Eurofins Scientific
Janvier Labs
genOway
Hera BioLabs
Inotiv, Inc.
Psychogenics
TransCure bioServices
These companies are strengthening their market positions through customized animal-model development, genetically modified strains, humanized models, contract research services, and integrated preclinical testing capabilities.
Investment Analysis and Opportunities
The Animal Model Market is attracting investment from pharmaceutical and biotechnology companies because of growing demand for reliable preclinical models in drug discovery, toxicology, oncology, immunology, and precision medicine.
Key Investment Opportunities
Genetically engineered mice
Humanized mouse models
Patient-derived xenografts
Customized disease models
CRISPR-based model development
Immunodeficient animal models
Oncology research models
Infectious-disease models
Neurological disease models
Contract research services
Preclinical testing services
Digital animal phenotyping
The expansion of cell and gene therapies, immuno-oncology, personalized medicine, and rare-disease research is creating additional demand for highly specialized models. CROs also represent an attractive opportunity as pharmaceutical companies increasingly outsource preclinical studies.
New Product Development
Product development in the Animal Model Market is increasingly focused on improving how closely laboratory models reproduce human disease biology. Advances in gene editing, genomics, and immunology are allowing companies to develop more precisely engineered models.
Key areas of development include:
CRISPR-engineered animal models
Humanized immune-system models
Patient-derived xenograft models
Genetically humanized mice
Immunodeficient strains
Multi-gene disease models
Precision oncology models
Customized transgenic models
Advanced behavioral-monitoring systems
Digital phenotyping platforms
Automated animal-monitoring systems
Companies are also combining animal models with genomic sequencing, artificial intelligence, imaging, and digital phenotyping to collect more comprehensive data and improve the reproducibility of preclinical research.
Five Recent Industry Developments
Recent industry activity has focused on genetically engineered models, customized research services, and expansion of preclinical capabilities:
Expansion of humanized models: Animal-model providers are increasing their portfolios of humanized mice for oncology, immunology, infectious-disease, and immunotherapy research.
Growth of CRISPR-based model development: Gene-editing technologies are being increasingly adopted to produce customized disease models more rapidly.
Expansion of oncology-model services: CROs are increasing their use of patient-derived xenograft and genetically engineered mouse models to support cancer-drug development.
Growth of digital phenotyping: Research organizations are adopting automated imaging, activity monitoring, and behavioral-analysis systems to improve data collection.
Expansion of preclinical outsourcing: Pharmaceutical and biotechnology companies are increasingly outsourcing breeding, model development, toxicology, and efficacy studies to specialized CROs.
Request Sample Report
Future Outlook
According to Fortune Business Insights, the global Animal Model Market was valued at USD 2.69 billion in 2025 and is projected to grow from USD 2.93 billion in 2026 to USD 5.87 billion by 2034, exhibiting a CAGR of 9.07% during the forecast period.
Continued Dominance of Mice
Mice account for nearly 71% of the global market, making them the leading animal type. Their genetic similarity to humans, rapid reproduction, availability of established strains, and compatibility with genetic engineering will continue to support their widespread use.
Growth of Guinea Pig Models
Guinea pigs contribute approximately 18% of the market. Their use in respiratory disease, infectious disease, immunology, allergy, vaccine, and dermatology research will continue to support demand.
Expansion of Genetically Engineered Models
Genetically engineered models will remain a major growth area as researchers require increasingly precise representations of human diseases. CRISPR and other gene-editing techniques are making it possible to create targeted genetic modifications for specialized research applications.
Growth of Humanized Mouse Models
Humanized mice are expected to gain greater adoption in oncology, immunology, infectious diseases, and immunotherapy. These models can provide researchers with more human-relevant biological responses than conventional laboratory strains.
Increasing Demand for Patient-Derived Xenografts
Patient-derived xenografts will remain important for cancer research and precision medicine. These models can help researchers evaluate the response of tumor-derived material to different therapeutic approaches.
Cancer Research Remains the Leading Application
Cancer research accounts for approximately 46% of the global Animal Model Market.
The expansion of targeted therapies, immunotherapy, antibody-drug development, and personalized oncology will continue to support demand for advanced oncology models.
Increasing Use in Infectious Disease Research
Animal models will continue to play an important role in vaccine development, antimicrobial testing, infectious-disease research, and study of host-pathogen interactions.
The development of models for emerging infectious diseases will create additional opportunities for specialized providers.
Expansion of Immunology Research
The growth of immunotherapy and immune-targeting medicines is increasing demand for humanized and immunodeficient animal models. These models are increasingly used for studying immune responses and evaluating therapeutic candidates.
Growth of Neurological Disease Models
Customized animal models for neurological and neurodegenerative diseases are expected to see growing adoption as pharmaceutical companies increase investment in neuroscience research.
Models for diseases such as Alzheimer's disease, Parkinson's disease, and other neurological disorders can support the investigation of disease mechanisms and therapeutic responses.
Increasing Adoption of CRISPR Gene Editing
CRISPR technology is expected to remain a major technological driver. It enables targeted genetic modification and can accelerate creation of models that reproduce specific disease-associated mutations.
Growth of Precision Medicine
Precision medicine is creating demand for animal models that reproduce specific genetic and molecular characteristics of individual diseases or patient populations.
Customized models can help researchers study treatment response and resistance mechanisms.
Increasing Adoption of Digital Phenotyping
Digital phenotyping, automated imaging, motion tracking, and behavioral monitoring are expected to become increasingly important. These technologies allow researchers to collect more detailed and standardized behavioral and physiological measurements.
Expansion of Contract Research Organizations
CROs are expected to capture additional market opportunities as pharmaceutical and biotechnology companies outsource breeding, model development, efficacy testing, and toxicology studies.
This outsourcing trend can allow drug developers to access specialized models and technical expertise without maintaining large internal facilities.
Increasing Integration of Artificial Intelligence
AI and machine learning are increasingly being used to analyze animal-study data, identify patterns, quantify phenotypes, and support experimental design.
The integration of AI with animal models may improve research efficiency and interpretation of complex biological datasets.
Growth of Automated Laboratory Systems
Automated housing, monitoring, imaging, and data-collection systems are expected to increase efficiency in research facilities. Automation can also improve consistency in experimental observations and reduce manual workloads.
Increasing Demand for Standardized Models
Pharmaceutical companies and regulatory authorities are placing greater emphasis on reproducibility and standardized preclinical research. Validated strains, controlled laboratory conditions, and consistent study protocols are therefore expected to remain important.
Increasing Focus on Alternatives to Animal Testing
Ethical concerns and regulatory requirements are encouraging investment in organoids, organ-on-chip systems, computational models, and in-vitro testing.
Although these alternatives are expanding, animal models are expected to remain important for complex interactions involving whole-organism physiology, pharmacokinetics, immune responses, and toxicology.
Challenge from Ethical and Regulatory Requirements
Animal welfare regulations can increase facility-management costs, documentation requirements, staffing needs, and research timelines. Providers must comply with strict standards covering animal housing, veterinary oversight, humane procedures, and experimental design.
Challenge from High Maintenance Costs
Maintaining specialized animal colonies requires controlled environments, biosecurity systems, veterinary services, specialized personnel, and breeding programs. Genetically modified and immunodeficient models can be particularly expensive to maintain.
Challenge from Reproducibility and Translational Limitations
Animal-model results do not always translate directly to human clinical outcomes. Differences in physiology, immune response, metabolism, and disease mechanisms can reduce predictive value.
Consequently, researchers are increasingly combining animal models with human-cell systems, organoids, computational tools, and clinical data.
Regional Growth Opportunities
In 2025, North America held approximately 41%, Europe 28%, Asia Pacific 23%, and Rest of World 8% of the global Animal Model Market.
North America
North America remains the leading market due to its extensive pharmaceutical and biotechnology ecosystem, advanced research infrastructure, specialized laboratory facilities, and strong government funding for biomedical research.
The U.S. remains the primary contributor, with demand driven by oncology, immunology, infectious diseases, gene therapy, and precision medicine research.
Europe
Europe accounts for approximately 28% of the global market. Strong pharmaceutical R&D, academic research institutions, biotechnology clusters, and translational medicine programs support demand for animal models.
Germany represents approximately 31% of Europe's market, while the U.K. accounts for approximately 24%.
Asia Pacific
Asia Pacific represents approximately 23% of the market and offers strong growth opportunities due to expanding pharmaceutical manufacturing, biotechnology investments, CRO activities, and preclinical research infrastructure.
Japan represents approximately 27% of Asia Pacific's market, while China accounts for approximately 18%.
China and other Asian markets are expanding research capabilities in oncology, vaccines, infectious diseases, and genetically engineered animal models.
What’s Driving Japan’s Market? Discover the Latest Animal Model Market Insights
Comments